MedTech Dive January 22, 2026
Pricing challenges in Abbott’s nutrition business and lower than expected sales of continuous glucose monitors drove down the company’s shares.
Abbott’s fourth quarter sales came in below expectations, as the company navigated challenges in its nutrition and diagnostics businesses. Abbott also reported less growth than expected in its medical devices segment.
The company’s revenue of $11.46 billion for the quarter fell short of analysts’ consensus of $11.8 billion, Leerink Partners analyst Mike Kratky wrote in a research note on Thursday. Abbott’s shares opened at $107.53 on Thursday, down nearly 11% from Wednesday’s closing price.
RBC Capital Markets analyst Shagun Singh wrote to clients that sales in Abbott’s nutrition, diagnostics and medical devices business all were below expectations, with the...
Today's Sponsors
Today's Sponsor